 Galmed Pharmaceuticals Ltd. Nasdaq: GLMD Galmed or the Company, a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in a Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis NASH and fibrosis announced today that it will host a conference call and webcast on Thursday, August 6, 2020, to provide an update on current developments with respect to its clinical programs for AramcholTM and to discuss financial results for the three and six months ended June 30, 2020. 